Ascendis Pharma A/S Book Value Per Share Growth & History (ASND)
Ascendis Pharma A/S's book value per share was -€2.63 for fiscal 2025.
View full Ascendis Pharma A/S company overviewAscendis Pharma A/S annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -€2.63 | -€0.89 | — |
| 2024 | 2024-12-31 | -€1.74 | €0.78 | — |
| 2023 | 2023-12-31 | -€2.52 | -€7.13 | — |
| 2022 | 2022-12-31 | €4.61 | -€10.91 | −70.31% |
| 2021 | 2021-12-31 | €15.52 | -€0.08 | −0.54% |
| 2020 | 2020-12-31 | €15.60 | €3.16 | +25.40% |
| 2019 | 2019-12-31 | €12.44 | €5.80 | +87.22% |
| 2018 | 2018-12-31 | €6.65 | €1.58 | +31.30% |
| 2017 | 2017-12-31 | €5.06 | -€1.59 | −23.86% |
| 2016 | 2016-12-31 | €6.65 | €1.59 | +31.32% |
| 2015 | 2015-12-31 | €5.06 | — | — |
Ascendis Pharma A/S quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €21.87 | €24.97 | — |
| Q1 2026 | 2026-03-31 | €7.90 | €11.04 | — |
| Q4 2025 | 2025-12-31 | -€2.63 | -€0.89 | — |
| Q3 2025 | 2025-09-30 | -€2.85 | -€1.16 | — |
| Q2 2025 | 2025-06-30 | -€3.10 | €2.50 | — |
| Q1 2025 | 2025-03-31 | -€3.14 | €1.04 | — |
| Q4 2024 | 2024-12-31 | -€1.74 | €0.78 | — |
| Q3 2024 | 2024-09-30 | -€1.69 | -€0.39 | — |
| Q2 2024 | 2024-06-30 | -€5.60 | -€6.75 | — |
| Q1 2024 | 2024-03-31 | -€4.19 | -€7.17 | — |
| Q4 2023 | 2023-12-31 | -€2.52 | -€7.13 | — |
| Q3 2023 | 2023-09-30 | -€1.30 | -€9.39 | — |
| Q2 2023 | 2023-06-30 | €1.15 | -€9.74 | −89.41% |
| Q1 2023 | 2023-03-31 | €2.98 | -€8.88 | −74.87% |
| Q4 2022 | 2022-12-31 | €4.61 | -€10.91 | −70.31% |
| Q3 2022 | 2022-09-30 | €8.09 | -€9.38 | −53.70% |
| Q2 2022 | 2022-06-30 | €10.89 | -€1.86 | −14.60% |
| Q1 2022 | 2022-03-31 | €11.86 | -€3.05 | −20.46% |
| Q4 2021 | 2021-12-31 | €15.52 | -€0.08 | −0.54% |
| Q3 2021 | 2021-09-30 | €17.47 | -€0.35 | −1.94% |
| Q2 2021 | 2021-06-30 | €12.75 | €2.89 | +29.23% |
| Q1 2021 | 2021-03-31 | €14.91 | €3.48 | +30.40% |
| Q4 2020 | 2020-12-31 | €15.60 | €3.16 | +25.40% |
| Q3 2020 | 2020-09-30 | €17.81 | €3.97 | +28.68% |
| Q2 2020 | 2020-06-30 | €9.87 | -€4.33 | −30.49% |
| Q1 2020 | 2020-03-31 | €11.44 | -€5.09 | −30.78% |
| Q4 2019 | 2019-12-31 | €12.44 | €5.80 | +87.22% |
| Q3 2019 | 2019-09-30 | €13.84 | €6.61 | +91.29% |
| Q2 2019 | 2019-06-30 | €14.20 | €6.26 | +78.82% |
| Q1 2019 | 2019-03-31 | €16.52 | €7.55 | +84.06% |
| Q4 2018 | 2018-12-31 | €6.65 | €1.58 | +31.30% |
| Q3 2018 | 2018-09-30 | €7.24 | — | — |
| Q2 2018 | 2018-06-30 | €7.94 | — | — |
| Q1 2018 | 2018-03-31 | €8.98 | — | — |
| Q4 2017 | 2017-12-31 | €5.06 | €0.29 | +6.00% |
| Q4 2016 | 2016-12-31 | €4.78 | — | — |
Ascendis Pharma A/S book value per share trends
Over the last five fiscal years, Ascendis Pharma A/S's book value per share decreased from €15.60 to -€2.63, a change of -€18.23. The latest reported quarter, Q2 2026, shows €21.87.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ascendis Pharma A/S source filings ↗